Pharmacotherapy of spasticity: some theoretical and practical considerations.
The availability of new antispasticity agents has greatly extended the therapeutic arm of the neurologist and has obviated the need for destructive neurosurgical procedures in many instances. Baclofen remains the single most useful agent, but in certain circumstances, benzodiazepines and dantrolene sodium are useful alternative or adjunctive treatments. Tizanidine has been recently introduced, and early experience with this agent appears to be favourable. A variety of new drugs are awaiting further evaluation. The effective use of these agents demands an understanding of their principal mechanisms of action, knowledge of their predictable side effects, and a familiarity with the underlying neurological disorders. The monitoring of clinical efficacy is difficult and is often dependent upon subjective evaluation. The application of electrophysiological studies might facilitate the monitoring of treatment and the prediction of optimum treatment strategies for individual patients. The use of these pharmacological agents, from the perspective of a clinician, will be discussed.
Rice
G P
GP
Department of Clinical Neurological Sciences, University Hospital, London, Ontario, Canada.
D001418:Baclofen / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use*; D003000:Clonidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003620:Dantrolene / Q000627:therapeutic use*; D006801:Humans; D009128:Muscle Spasticity / Q000188:drug therapy*; D010276:Parasympatholytics / Q000627:therapeutic use
D010276:Parasympatholytics; D001569:Benzodiazepines; C023754:tizanidine; D003620:Dantrolene; D001418:Baclofen; D003000:Clonidine